Compare BBOT & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBOT | SABR |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 717.8M | 835.4M |
| IPO Year | 2024 | 2014 |
| Metric | BBOT | SABR |
|---|---|---|
| Price | $9.08 | $2.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $24.00 | $1.50 |
| AVG Volume (30 Days) | 248.1K | ★ 3.9M |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 99.93 | ★ 283.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,866,956,000.00 |
| Revenue This Year | N/A | $7.51 |
| Revenue Next Year | N/A | $3.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $7.00 | $0.81 |
| 52 Week High | $14.87 | $2.30 |
| Indicator | BBOT | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 55.22 |
| Support Level | $7.99 | $1.54 |
| Resistance Level | $9.49 | $2.26 |
| Average True Range (ATR) | 0.48 | 0.15 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 53.70 | 43.66 |
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.